New report projects 12.6% increase of probiotics market
NEW YORK The two takeaways from this story are “the [U.S.] market is expected to grow at a rate of almost 14%” and “the early movers in the industry will benefit in terms of market share.”
That about describes the opportunity in a probiotic nutshell.
The rising interest in probiotics can be credited in part to Dannon’s Activia brand, a line of yogurts and yogurt drinks, which has been heavily advertised to the American consumer with the message that not all bacteria is bad for you — and in fact some bacteria taken on a regular basis can impart some pretty significant health benefits. That advertising message — that probiotics can be an important piece in a healthier-for-you diet — has been all the more reinforced as Bayer supports its probiotic Phillips Colon Health, and as Procter & Gamble rolls out its Align probiotic.
And the consumers already are core drug store shoppers. The ratio of women to men in search of a product delivering digestive benefits is about 2-to-1, according to industry experts. When women hit their 30s and 40s, that’s the point in their lives when they’re looking for a strategy in life to help them manage their digestive issues.
Medco report: Specialty pharmacy spending driven by cancer drugs
FRANKLIN LAKES, N.J. Cancer drugs will become the biggest driver of specialty pharmacy spending, with global sales of the drugs expected to reach $80 billion by 2012, according to a new report by pharmacy benefit manager Medco Health Solutions.
Spending on cancer drugs increase by 15.1% last year – behind autoimmune disorder and multiple sclerosis drugs – with an overall contribution to drug spending of 5% during the first half of this year.
“Targeted cancer therapies have dramatically reshaped oncology and greatly benefited cancer patients,” Medco chief medical officer Robert Epstein said in a statement. “The newer cancer drugs improve survival rates since they target what fuels the cancer’s growth.”
Cancer drugs also represent a robust pipeline, with more than 800 under investigation. Many of the drugs that the Food and Drug Administration has approved in the last four years – often biotech drugs – have cost $20,000 for 12-week courses of therapy, while some have cost $10,000 a month, though the report said a regulatory approval pathway for biosimilars could help reduce the costs of biotech drug treatments.
Kinney Drugs to purchase Vermont retail pharmacy
GOUVERNEUR, N.Y. A regional retail pharmacy chain in northern New York state will purchase a locally owned store in Vermont.
Kinney Drugs announced Wednesday that it would purchase Vincent’s Drug & Variety, in Waterbury, Vt. The purchase is expected to take place in early January 2010.
“Everyone at Kinney Drugs is excited at the prospect of welcoming Vincent’s Drug employees and customers into our family,” Kinney Drugs president and COO Bridget-ann Hart said in a statement. “It is important to us that this transition be as smooth as possible for both Vincent’s Drug customers and its employees.”
Vincent’s Drug & Variety has been in Waterbury for 98 years.
“The values, health programs and services and community involvement of our two companies are very much aligned,” owner and pharmacist John Vincent said in a statement. “I wholeheartedly trust the people of Kinney Drugs to provide the same level of caring that Washington County has become accustomed to from Vincent’s Drug & Variety.”